About M8 Pharmaceuticals
M8 Pharmaceuticals is a company based in Berwyn (United States) founded in 2007 was acquired by Acino in December 2023. M8 Pharmaceuticals has raised $264.41 million across 9 funding rounds from investors including Teva Pharmaceuticals, TPG and Knight Therapeutics. M8 Pharmaceuticals offers products and services including Innovative Medicines and Partnership Services.
- Headquarter Berwyn, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name M8 Pharmaceuticals, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$264.41 M (USD)
in 9 rounds
-
Latest Funding Round
$25 M (USD), Debt – Conventional
Feb 01, 2019
-
Investors
Teva Pharmaceuticals
& 4 more
-
Employee Count
Not available
-
Acquired by
Acino
(Dec 04, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of M8 Pharmaceuticals
M8 Pharmaceuticals offers a comprehensive portfolio of products and services, including Innovative Medicines and Partnership Services.
Innovative medicines are developed and commercialized in therapeutic areas like Central Nervous System and Oncology
Strategic partnerships are formed for licensing and commercialization of medicines in global markets
Funding Insights of M8 Pharmaceuticals
M8 Pharmaceuticals has successfully raised a total of $264.41M across 9 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $25 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in M8 Pharmaceuticals
M8 Pharmaceuticals has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Teva Pharmaceuticals, TPG and Knight Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Fund of funds focused on pre-seed and seed-stage companies
|
Locked | Locked | Locked | |
|
Prescription pharmaceuticals are acquired, licensed, and commercialized by the company.
|
Locked | Locked | Locked | |
|
Pharmaceutical formulations are developed and marketed by Forest Laboratories.
|
Locked | Locked | Locked |
Investor details for M8 Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by M8 Pharmaceuticals
Investment portfolio details for M8 Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - M8 Pharmaceuticals
Detailed financials for M8 Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
M8 Pharmaceuticals Comparisons
Peer comparison for M8 Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of M8 Pharmaceuticals
Detailed competitors of M8 Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on M8 Pharmaceuticals
Complete news archive for M8 Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about M8 Pharmaceuticals
M8 Pharmaceuticals was founded in 2007 and raised its 1st funding round 1 year after it was founded.
M8 Pharmaceuticals is headquartered in Berwyn, United States. It is registered at Berwyn, Illinois, United States.
Joel Barlan is the current CEO of M8 Pharmaceuticals.
M8 Pharmaceuticals is a funded company, having raised a total of $264.41M across 9 funding rounds to date.
M8 Pharmaceuticals was founded in 2007 and is headquartered in Berwyn, United States. Operations in the pharmaceutical sector involve partnerships with other companies to develop and commercialize original medicines. Access to established treatments is facilitated for patients across Latin America, with a focus on regional distribution and market entry strategies. Leadership is provided by CEO Joel Barlan.
M8 Pharmaceuticals offers Innovative Medicines and Partnership Services.
M8 Pharmaceuticals has 5 investors. Key investors include Teva Pharmaceuticals, TPG, Knight Therapeutics, Forest Laboratories, and Acino.